



Fourth Quarter 2025


Aker BioMarine ASA
12th February 2026

Q4 2025 highlights

- Fourth quarter:
 - Revenues of USD 55.2 million (up 6% YoY)
 - Adjusted EBITDA of USD 10.6 million (up 66% YoY)
- Full year 2025:
 - Revenues of USD 218.1 million (up 10% YoY)
 - Adjusted EBITDA of USD 45.7 million (up 53% YoY)
- Fourth quarter segment highlights:
 - Human Health Ingredients: Revenues of USD 32.7 million (up 28%). Adjusted EBITDA of USD 14.1 million (up 59% YoY)
 - Consumer Health Products: Revenues of USD 26.9 million (down 8% YoY). Adjusted EBITDA of USD 2.5 million
 - Emerging Business: Revenues of USD 2.0 million, stable from previous quarters. Adjusted EBITDA of USD -0.5 million
- Following recent interest in the Human Health Ingredient business unit, the Company has engaged advisers to support exploring alternatives and work towards a transaction in 2026




Quarterly revenue and Adjusted EBITDA (USDm)



Note: 1) Akter BioMarine evaluates the performance based on Adjusted EBITDA. This metric is defined as operating profit before depreciation, amortization, write-downs and impairments, and special operating items. Special operating items include gains or losses on sale of assets, if material, restructuring expenses and other material transactions of either non-recurring nature or special in nature compared to ordinary operational income or expenses.

Annual revenue and Adjusted EBITDA (USDm)



1

Operations




Human Health Ingredients (USDm)


Commentary

- Total revenue growth of 28% YoY
- Krill oil equivalent revenues increased 28% YoY
 - Growth driven by both volume and price
 - Price growth skewed by significantly higher share of capsule sale in the quarter
- Supplied significant volumes of Superba Krill Oil to new krill oil brand – successful listing in Costco
- Gross margin up from last year, but down from previous quarter on product mix
- Adj. EBITDA improved from last year on better gross margins
- Algae sales of USD 1.6m in quarter to Epion - pipe fill for launch of new SKU in 2026
- Lysoвета named “the Innovation Winner” at the CMA Annual Conference
- Clinical results showing 7–8x higher absorption when silymarin is delivered with our PL+ technology

Revenue



EBITDA adj.¹




Consumer Health Products (USDm)




Commentary

- Revenue decline of 8% YoY
 - Growth below expectations, driven by continued weakness in drug chains, inventory builddown at Epion, and delayed new customer launches (Whole Foods, BJ's) from late 2025 to early 2026
 - Solid underlying performance in consumer health product SKUs, with a strong pipeline of new product wins across retail chains for 2026
 - Full year revenues in 2025 on par with 2024
- Improved gross margin on customers mix and higher EBITDA margin on good cost control
 - Good cost control, SG&A 6% lower than in 2022

Revenue



EBITDA adj.¹



Note: 1) 2024 numbers restated based on updated cost allocation to ensure comparability with 2025, unaudited.


Emerging Business (USDm)

Commentary


- Stable development in revenue and demand for Kori
- Kori continues path towards profitability
- Understory: Sales process still ongoing with several interest parties



Revenue



EBITDA adj.¹



2

Financials

Profit & loss statement¹

Net sales

- Net sales were up 6% from Q4-24. Net sales in the Human segment are up 28% due to higher volume and price of Superba krill oil. The Consumer health segment is down 8% compared to same quarter last year. Net sales in the Emerging business segment is down 13% vs last quarter last year.

Cost of goods sold

- Cost of goods sold is lower compared to same quarter last year despite higher revenues due to improved Houston production. Higher gross margins due to higher sales of Superba in the Human Health segment. Slightly higher margins in the Consumer Health segment while margins in Emerging businesses are down.

SG&A

- SG&A costs are lower than last year due to cost efficiencies, especially in Human Health. Higher costs in the Consumer Health segment, while costs in the Emerging business segment are reduced.

Depreciation, amortization and impairment

- Intangible assets amortized according to plan. Depreciation on production-related assets included in cost of goods sold. No depreciations on Understory as classified as held for sale.

Net financial items

- Net financial items are related to interests on bond, FX and net loss in associated companies.

Tax expense

- Tax expense is related to US and Spain operations.

Profit from discontinued operations

- Includes net result from Understory including an impairment of USD 15 million in Q2-25. FY2024 also includes net result (incl. gain) from Feed Ingredients transaction.

Adjustments

- Adjustments in the quarter are related to restructuring and M&A preparations.

USD million	Q4 2025	Q4 2024*	FY 2025	FY 2024*
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Net sales	55.2	52.0	218.1	199.0
Cost of goods sold	-30.6	-31.8	-120.3	-120.6
Gross profit	24.6	20.1	97.8	78.4
SG&A	-17.0	-20.4	-69.1	-68.0
Depreciation, amortization and imp. (non-production assets)	-4.7	-4.9	-18.0	-16.6
Other operating income	0.2	0.8	2.0	2.0
Operating profit (loss)	3.1	-4.3	12.8	-4.2
Net financial items	-6.6	-8.3	-15.7	-7.9
Tax expense	-1.5	0.7	0.0	0.1
Net profit (loss) from continued operations	-5.0	-11.9	-2.8	-12.0
Net profit (loss) from discontinued operations	-0.5	-5.2	-20.0	194.6
Net profit (loss)	-5.6	-17.0	-22.8	182.6
EBITDA reconciliation				
Operating profit	3.1	-4.3	12.8	-4.2
Depreciation, amortization and imp.	4.7	4.9	18.0	16.6
D&A and imp. from production assets incl. in COGS	1.3	1.8	5.0	5.7
EBITDA (unadjusted)	9.1	2.4	35.8	18.1
Adjustments	1.5	4.0	10.0	11.8
EBITDA (adjusted)	10.6	6.4	45.8	29.9


Non-operational segment: Elim / other (Corporate cost)

- Higher SG&A in Q4, somewhat impacted by seasonality
- SG&A includes costs from ongoing restructuring programs and M&A preparations that are adjusted out
- TSA income from Aker Qrill Company ceased as agreement is now terminated
- EBITDA adjusted includes USD -1.1 million in internal profit elimination


Allocation of corporate costs:

- Each segment reports SG&A costs directly attributable to their operations and FTE resources
- All overhead and corporate cost (finance, legal, ESG, HR, communication and IT compliance) is booked under "Other/elim" with the exception of the Consumer Health Segment

SG&A¹ including non-recurring costs (USDm)




EBITDA adjusted¹ (USDm)




Working capital

- Lower NWC in quarter as as both inventory and accounts receivables are down, while payables are up.

Change in net working capital (USDm)




Net working capital (USDm)



Investments

- Capex in the quarter mainly related to maintenance, improvements in production line and capitalization of development projects
- Full year review of development activities led to certain adjustments between quarters
- 2026 capex expected to be at comparable levels to 2025
- Ongoing feasibility study to evaluate long term capacity alternatives for Houston plant


Capex, tangible and intangible (USDm)¹



Cash flow

- Cash flow from operations of USD 9.7 million
 - Driven by working capital release
- Cash flow from investing
 - Capex in quarter mainly related to maintenance, improvement in production line and capitalization of development projects
- Cash flow from financing
 - Mainly repayment on overdraft
- Total available liquidity of USD 25 million
- Ongoing implementation of mitigating actions to reduce tariff impact. Current assessment indicates modest effects, approx. 10% of the import value of the raw material into Houston


Cash flow in the quarter (USDm)



Interest-bearing debt

- Net interest-bearing debt of USD 157 million
 - Down from previous quarter on lower working capital
- NIBD/Adj. EBITDA of 3.5x
 - Well below leverage covenant test for the bank overdraft
 - No leverage covenant on bond
 - In compliance with the bond liquidity covenant of USD 7.5 mill

Interest-bearing debt¹⁾ (USDm)



Balance Sheet

Property, plant and equipment

- Mainly related to equipment for Houston production. Protein plant is included in assets held for sale.

Intangible assets and goodwill

- Customer contracts and development projects amortized according to plan. In 2025 there have been reclassifications from intangible asset to asset under construction. Development work, mainly related to algae, is capitalized.

Contract asset

- Includes contracts related to new customers and/or markets.

Inventories

- Higher inventory in the Human Health segment due to strong Houston production. Higher inventory in the Consumer Health segment to prepare for new customer launches in Q1.

Cash and cash equivalents

- Cash and cash equivalents were USD 16,9 mill. Net interest-bearing debt (including leasing and derivative asset) was USD 157 mill, of which bond placed in Q3'24 of NOK 1,600m.

Assets held for sale

- Includes the Group's investment in Understory protein classified as 'assets held for sale' and 'liabilities held for sale'.

Equity ratio of 37%

USD million	Q4 2025 (Unaudited)	Q4 2024* (Unaudited)
ASSETS		
Property, plant and equipment	53.7	49.0
Right to use assets	2.6	2.6
Intangible assets and goodwill	116.9	123.4
Contract asset	2.3	1.2
Deferred tax asset	2.3	5.7
Derivative asset	8.2	-
Other interest-bearing non-current receivables	4.1	3.3
Other non-current receivables	3.6	-
Investments in equity-accounted investees	2.2	0.4
Total non-current assets	196.0	185.7
Inventories	107.2	89.3
Trade receivable and prepaid expenses	47.3	54.2
Current interest-bearing receivables	1.4	0.9
Cash and cash equivalents	16.9	15.0
Assets held for sale	17.3	35.3
Total current assets	190.1	201.8
TOTAL ASSETS	384.9	380.4
LIABILITIES AND OWNERS' EQUITY		
Interest-bearing debt	159.3	140.3
Deferred tax liability	4.5	8.3
Derivative liability	-	11.8
Total non-current liabilities	163.8	160.3
Interest-bearing current liabilities	22.9	7.2
Accounts payable and other payables	50.9	42.6
Liabilities held for sale	3.4	3.4
Total current liabilities	77.0	53.2
TOTAL LIABILITIES	241.0	213.6
Total equity	143.9	166.9
TOTAL EQUITY AND LIABILITIES	384.9	380.4



Summary and Outlook


Outlook

Operating segments



Corporate

- Corporate segment with underlying cost level at USD 12-14 million
- Following recent interest in the Human Health Ingredient business unit, the Company has engaged Jefferies and Houlihan Lokey as investment banks to support the Company in exploring alternatives and work towards a transaction in 2026



Q&A

To submit questions, please send to
ir@akerbiomarine.com

4 Appendix



Cash flow¹

Cash flow from operations

- Positive cash flow from operations
- Interest paid includes interest on bond amounting to USD 3.4 mill.
- Change in working capital is mainly due to reduced inventory (Nutra consumption and high sales), reduced AR and higher AP.

Cash flow from investing activities

- Investments on ongoing projects mainly on Houston production related equipment and development projects

Cash flow from financing activities

- Mainly repayment on overdraft in Q4
- Instalment interest-bearing debt is leasing payments

Total available liquidity USD 25 million

USD million-	Q4 2025	Q4 2024*	2025	2024*
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Net profit (loss)	-5.6	-17.0	-22.8	182.6
Tax expenses	1.5	-0.7		-0.1
Net interest and guarantee expenses	4.2	8.0	15.3	24.9
Interest paid	-4.3	-3.0	-15.8	-24.3
Interest received	-1.4	1.9	0.6	4.4
Other P&L items with no cash flow effect	-6.1	-2.3	-7.7	-204.3
Depreciation, amortization and impairment	8.5	5.4	40.7	47.8
Change in working capital	12.8	6.3	-5.8	-18.7
Net cash flow from operating activities	9.7	-3.4	4.4	12.2
Payments for property, plant and equipment	-1.8	-1.0	-6.1	-17.4
Payments for intangibles	-0.6	-0.2	-2.8	-5.7
Payments for new interest-bearing receivable	0.1	-0.8	-0.6	-1.0
Proceed from sale of subsidiaries incl dividend received				404.1
Payments from sale of subsidiaries			-7.3	
Investments in subsidiary and associated companies		0.4		-0.7
Other cash flow from investing activities				-
Net cash flow from investing activities	-2.3	-1.6	-16.8	379.4
Change in overdraft facility and other short-term debt	-6.4	5.7	16.9	3.5
Instalment interest-bearing debt	-1.5	-0.6	-2.6	-185.0
Proceeds from issue of external interest-bearing debt				150.7
Dividend paid				-373.2
Net cash flow from financing activities	-7.9	5.1	14.3	-404.0
Net change in cash	-0.5	0.1	1.9	-12.5
Cash in the beginning of the period	17.4	14.9	15.0	27.5
Cash at the end of the period	16.9	15.0	16.9	15.0

Alternative performance measures (APMs)

- Total special operating items in Q3 2025 was USD 1.6 million, mainly related to ongoing restructuring programs and M&A preparations.
- APMs recognized in 2024 were costs mainly related to the improvement program and the strategic review of the Feed Ingredient business.
- For further details on APMs in 2024, see the group financial statements for 2024.

USDm	Q4		Year	
	2025	2024*	2025	2024*
Operating profit (loss)	3.1	-4.3	12.8	-4.2
Depreciation, amortization and impairment	6.0	6.7	23.0	22.3
EBITDA	9.1	2.4	35.8	18.1
Special operating items	1.5	4.0	10.0	11.8
Adjusted EBITDA	10.6	6.4	45.8	29.9

USDm	Q4		YTD		Year
	2025	2024 ¹	2025	2024 ¹	2024 ¹
Restructuring costs	1.8	3.0	9.8	8.9	1.8
Inventory effects and product impairment	-	0.7	0.2	2.6	-
Other	-0.3	0.3	-0.1	0.3	-0.3
Total special operating items	1.5	4.0	10.0	11.8	1.5

Important information

This presentation has been prepared by Aker BioMarine ASA (the "Company"). The presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or any of its subsidiaries nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any of its subsidiaries, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be or should be placed by any person for any purposes whatsoever on the information contained in this presentation, or on its completeness, accuracy or fairness.

This presentation contains summary information only and does not purport to be comprehensive and is not intended to be (and should not be used as) the sole basis of any analysis or other evaluation. No representation, warranty, or undertaking, express or implied, is made by the Company, its affiliates or representatives as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein, for any purpose whatsoever. Neither the Company nor any of its affiliates or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss whatsoever and howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. All information in this presentation is subject to updating, revision, verification, correction, completion, amendment and may change materially and without notice. In giving this presentation, none of the Company, its affiliates or representatives undertake any obligation to provide the recipient with access to any additional information or to update this presentation or any information or to correct any inaccuracies in any such information. The information contained in this presentation should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation.

Several factors could cause the actual results, performance or achievements that may be expressed or implied by statements and information in this Presentation. By reviewing this Presentation, you acknowledge that you will be solely responsible for your own assessment of the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business.

Matters discussed in this document and any materials distributed in connection with this presentation may constitute or include forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "continues", "should" and similar expressions. These forward-looking statements reflect the Company's beliefs, intentions and current expectations concerning, among other things, the Company's results of operations, financial condition, liquidity, prospects, growth and strategies. Forward-looking statements include statements regarding: objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; liquidity, capital resources and capital expenditures; economic outlook and industry trends; developments of the Company's markets; the impact of regulatory initiatives; and the strength of the Company's competitors. Forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. The forward-looking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in the Company's records and other data available from third parties. Although the Company believe that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Forward-looking statements are not guarantees of future performance and such risks, uncertainties, contingencies and other important factors could cause the actual results of operations, financial condition and liquidity of the Company or the industry to differ materially from those results expressed or implied in this presentation by such forward looking statements. No representation is made that any of these forward-looking statements or forecasts will come to pass or that any forecast result will be achieved and you are cautioned not to place any undue influence on any forward-looking statement.

This presentation and the information contained herein are not an offer of securities for sale in the United States and are not for publication or distribution to persons in the United States (within the meaning of Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act")). The securities referred to herein have not been and will not be registered under the Securities Act and may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. Neither this document nor any copy of it may be taken or transmitted into the United States, Australia, Canada or Japan or to any securities analyst or other person in any of those jurisdictions. Any failure to comply with this restriction may constitute a violation of United States securities laws. Neither this document nor any copy of it may be taken, released, published, transmitted or distributed, directly or indirectly, in or into the United States, Canada, Australia or Japan. Any failure to comply with this restriction may constitute a violation of United States, Canadian, Australian or Japanese Securities laws. This document is also not for publication, release or distribution in any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction nor should it be taken or transmitted into such jurisdiction and persons into whose possession this document comes should inform themselves about and observe any such relevant laws.

No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

This Presentation shall be governed by Norwegian law and any dispute arising in respect of this Presentation is subject to the exclusive jurisdiction of the Norwegian courts with Oslo District Court as legal venue.



AKER BIOMARINE